3104-LB: AdoXLong Platform Applied to Semaglutide for Once-Monthly Administrations
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-3104-lb ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von AUDREY MARECHAL und 12 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: AdoXLong technology is designed to deliver sustained peptide circulation for at least one month. This new long-acting peptide platform is based on a biocompatible polymer chemically linked to peptides of interest while maintaining their mechanism of action. AdoXLong was applied to semaglutide to develop a once-a-month formulation.
Methods
The bioactivity of AdoXLong Sema was determined in vitro by measuring cAMP production in GLP1-R overexpressing cells. Formulation was tested in rats following a subcutaneous injection. Plasma samples were analyzed by ELISA.
Results
In vitro, AdoXLong Sema demonstrates a high affinity to albumin. The intrinsic in vitro potency of GLP1-RA from AdoXLong Sema is well preserved and even slightly increased compared to semaglutide (Relative potency: 151%). A strong decrease of AdoXLong Sema in vitro potency is observed in the presence of human albumin, confirming its high affinity to albumin. Pharmacokinetic analysis of AdoXLong Sema after subcutaneous injection in rats shows an apparent half-life of 24h, i.e. 3.5 times that of semaglutide (Fig. 1).
Conclusion
These results indicate that AdoXLong Sema offers an effective strategy to extend the half-life and duration of action of semaglutide, potentially enabling once-monthly administration in humans. Disclosure A. Marechal: Employee; Current; ADOCIA. M. Gaudier: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. O. Soula: Board Member; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. Employee; Current; ADOCIA. C. Mégret: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. S. Hakim: Employee; Current; ADOCIA. Y. Chan: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. A. Gaffuri: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. B. Plancq: None. A. Martin: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. K. Lelu: Employee; Current; ADOCIA. J. Dutreuil: Employee; Current; ADOCIA. Stock/Shareholder; Current; ADOCIA. E. Dauty: Employee; Current; ADOCIA. U. Naessens: Employee; Current; ADOCIA.
Zitieren
APA
MARECHAL, A., GAUDIER, M., SOULA, O., MÉGRET, C., HAKIM, S., CHAN, Y., GAFFURI, A., PLANCQ, B., MARTIN, A., LELU, K., DUTREUIL, J., DAUTY, E., & NAESSENS, U. (2026). 3104-LB: AdoXLong Platform Applied to Semaglutide for Once-Monthly Administrations. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-3104-lb
Vancouver
MARECHAL A, GAUDIER M, SOULA O, MÉGRET C, HAKIM S, CHAN Y, et al. 3104-LB: AdoXLong Platform Applied to Semaglutide for Once-Monthly Administrations. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-3104-lb
BibTeX
@article{MARECHAL2026,
author = {MARECHAL, AUDREY and GAUDIER, MARTIN and SOULA, OLIVIER and MÉGRET, CLAIRE and HAKIM, SANA and CHAN, YOU-PING and GAFFURI, ANNE-LISE and PLANCQ, BAPTISTE and MARTIN, ALEXANDRE and LELU, KARINE and DUTREUIL, JEAN and DAUTY, EMMANUEL and NAESSENS, ULYSSE},
title = {3104-LB: AdoXLong Platform Applied to Semaglutide for Once-Monthly Administrations},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-3104-lb}
}
EUVIMED